Generic substitution in the treatment of epilepsy
- 12 August 2008
- journal article
- case report
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 71 (7), 525-530
- https://doi.org/10.1212/01.wnl.0000319958.37502.8e
Abstract
Objective: There are concerns that generic and brand antiepileptic drugs (AEDs) may not be therapeutically equivalent. This study investigated how generic AED substitution may have negative consequences.This publication has 14 references indexed in Scilit:
- What’s the problem with generic antiepileptic drugs?Neurology, 2007
- Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsyNeurology, 2007
- Compulsory Generic Switching of Antiepileptic Drugs: High Switchback Rates to Branded Compounds Compared with Other Drug ClassesEpilepsia, 2007
- Are there potential problems with generic substitution of antiepileptic drugs?: A review of issuesSeizure, 2006
- Patient and physician reactions to generic antiepileptic substitution in the treatment of epilepsyEpilepsy & Behavior, 2005
- Therapeutic equivalency of generic antiepileptic drugs: results of a surveyEpilepsy & Behavior, 2004
- Lower phenytoin serum levels in persons switched from brand to generic phenytoinNeurology, 2004
- Carbamazepine toxicity resulting from generic substitutionNeurology, 1993
- Assessment [RETIRED]Neurology, 1990
- Breakthrough seizure following substitution of Depakene capsules (Abbott) with a generic productNeurology, 1987